ライフサイエンスコーパス: pulmonary function

1 roup performance status of 0-2, and adequate pulmonary function.

2 make conclusions about the impact of IL33 on pulmonary function.

3 nd/or nerve function, physical function, and pulmonary function.

4 pregnancy demonstrate lifelong decreases in pulmonary function.

5 of current or former smokers with preserved pulmonary function.

6 n single nucleotide polymorphisms (SNPs) and pulmonary function.

7 included questionnaires, blood samples, and pulmonary function.

8 onally overlapped with those associated with pulmonary function.

9 e tested whether Htr4-null mice have altered pulmonary function.

10 ng exhaled nitric oxide, total serum IgE and pulmonary function.

11 ssive pulmonary fibrosis leading to impaired pulmonary function.

12 f nicotine on lung development and offspring pulmonary function.

13 onal responses, including cardiovascular and pulmonary function.

14 mean difference = -146 mm Hg; P = 0.076) or pulmonary function.

15 ients with elevated IgE levels and decreased pulmonary function.

16 monary function whereas the other had stable pulmonary function.

17 osition in the lungs, resulting in decreased pulmonary function.

18 ontrols, and the levels were correlated with pulmonary function.

19 roborated beneficial effects of n-3 PUFAs on pulmonary function.

20 ly of indicators of frailty, sarcopenia, and pulmonary function.

21 patients as potential imaging biomarkers for pulmonary function.

22 tment leads to tumor regrowth and decline in pulmonary function.

23 ies of wheezing, allergic sensitization, and pulmonary function.

24 tween severity of exposure and either LTL or pulmonary function.

25 o rebuild the epithelial barrier and restore pulmonary functions.

26 blood from 14 asthmatic patients with normal pulmonary function, 14 patients with COA, 11 patients in

27 of patients' arm anthropometrics, strength, pulmonary function, 6-minute-walk distance, and cognitiv

28 outcomes was highest for pulmonary (abnormal pulmonary function, 65.2% [95% CI, 60.4%-69.8%]), audito

29 5 years later, whereas exercise capacity and pulmonary function abnormalities were associated only wi

30 tematically evaluate changes in symptoms and pulmonary function after acute selective NSAID or COX-2

31 Pulmonary function and adverse event frequency did not c

32 egrating pathway-based methods with GWASs of pulmonary function and airflow obstruction would identif

33 N29 and KIM-127, is associated with impaired pulmonary function and airway eosinophilia, respectively

34 ing GWAS single-nucleotide polymorphisms for pulmonary function and analyzed associations with FEV1/F

35 tion marker CD203c inversely correlated with pulmonary function and body mass index in A fumigatus-se

36 ulmonary aspergillosis (ABPA), which affects pulmonary function and clinical outcomes.

37 ay inflammation induced by house dust mites, pulmonary function and cytokine profiles in Htr4-null mi

38 the impact of maternal smoking on offspring pulmonary function and decrease the incidence of wheeze

39 passive antibody and sulfasalazine improved pulmonary function and enhanced Pneumocystis clearance t

40 t destroyed sections of the lung can improve pulmonary function and exercise capacity but its benefit

41 chial-valve treatment significantly improved pulmonary function and exercise capacity in patients wit

42 The relationships between pulmonary function and imaging measurements were determi

43 lung development, with lifelong decreases in pulmonary function and increased asthma risk.

44 ta on symptoms, health care utilization, and pulmonary function and inflammation that were collected

45 poor clinical outcomes, including decreased pulmonary function and more severe disease.

46 hoalveolar lavage fluid that correlated with pulmonary function and nitric oxide levels, whereas HC-H

47 On day 1, subjects were assessed for pulmonary function and performed a maximal incremental c

48 ne-mediated senescent cell ablation improves pulmonary function and physical health, although lung fi

49 oth prophylactic and therapeutic RDV improve pulmonary function and reduce lung viral loads and sever

50 mSSPN overexpression improved pulmonary function and reduced dystrophic histopathology

51 en cGVHD model, ibrutinib treatment restored pulmonary function and reduced germinal center reactions

52 exploring the effects of poisonous gases on pulmonary function and related problems.

53 e effects of smoking in pregnancy on newborn pulmonary function and respiratory morbidities.

54 the relation of circulating CC16 levels with pulmonary function and responses to bronchial methacholi

55 beginning one month post-transplant restored pulmonary function and reversed lung fibrosis, which was

56 in the lung results in dramatically altered pulmonary function and structural alterations consistent

57 ed uptake value (SUVmax) was associated with pulmonary function and survival.

58 e the association between plasma 25(OH)D and pulmonary function and the effect modifications of sex a

59 to determine the effect of these clusters on pulmonary function and treatment response to inhaled ant

60 of WTC exposures, was associated with poorer pulmonary functioning and with greater subsequent declin

61 nonuclear cells (PBMCs) with the outcomes of pulmonary functions and overall survival, and used the m

62 e-operative evaluation of cardiovascular and pulmonary functions and post-operative fluid management

63 ologic (total and A fumigatus-specific IgE), pulmonary function, and body mass index measurements wer

64 toms (wheezing), aeroallergen sensitization, pulmonary function, and body mass index.

65 s; peripheral arterial endothelial function, pulmonary function, and coronary artery calcium were ass

66 between baseline biological, asthma control, pulmonary function, and demographic markers and responsi

67 ased lung inflammation, disrupted rhythms of pulmonary function, and emphysema.

68 ed, triggers pulmonary inflammation, reduces pulmonary function, and enhances lung injury by respirat

69 itial lung disease meeting defined dyspnoea, pulmonary function, and high-resolution CT (HRCT) criter

70 ips with asthma severity, airway morphology, pulmonary function, and magnetic resonance imaging (MRI)

71 a Zubrod performance status of 0-1, adequate pulmonary function, and no evidence of supraclavicular o

72 e how they contribute to age-related loss of pulmonary function, and pathogenesis of common age-relat

73 current or former smokers who had preserved pulmonary function as assessed by spirometry (FEV1:FVC >

74 ce, and were separable by varying degrees of pulmonary function as measured by imaging.

75 randomized to placebo (n = 83), had improved pulmonary function as measured by TPTEF:TE (0.383 vs 0.3

76 tissue motion analyses, to achieve regional pulmonary function assessment in beta-ENaC-overexpressin

77 induced wheezing episode are associated with pulmonary function at preschool age.

78 Changes from baseline in pulmonary function at Week 48 were analyzed by emphysema

79 None of the patients with declining pulmonary function attained the ability to hop or run; t

80 udy, and was further confirmed with COPD and pulmonary function-based family analyses, respectively.

81 For pulmonary function-based screening tools, FEV1/FEV6 was

82 Asthma outcomes included pulmonary function, bronchial reactivity, asthma symptom

83 Therapeutic LPV/RTV-IFNb improves pulmonary function but does not reduce virus replication

84 r(R) is a suitable DPI for patients with low pulmonary function but patients should be alert to avoid

85 essive mucus clogs small airways and reduces pulmonary function by decreasing oxygen exchange, leadin

86 ated traits in genome-wide studies including pulmonary function, cancers, inflammatory diseases, and

87 presence of asthma (case-control study) and pulmonary function (case-only study), adjusting for demo

88 e emphysema and fibrosis extents, as well as pulmonary function changes, over 48 weeks.

89 d with inducible STAT3-deficient T cells had pulmonary function comparable to the healthy negative co

90 Seven healthy volunteers with normal pulmonary function completed the study with evaluable da

91 Brachial artery endothelial function, pulmonary function, coronary artery calcium, and carotid

92 th systemic inflammatory markers and reduced pulmonary function, correlated with expression of genes

93 The relationship between pulmonary function data and CT densitometric changes in

94 0 Latino children (8-21y) with genotypic and pulmonary function data from the GALA II cohort.

95 the association between ILA progression and pulmonary function decline (and mortality).

96 tudy is associated with an increased rate of pulmonary function decline and increased risk of death.

97 lymorphism (SNP) in the CHRNA5/3/B4 locus on pulmonary function decline as mediated by cigarette smok

98 e length (LTL) is associated with more rapid pulmonary function decline in a longitudinal study of Wo

99 Pulmonary function decline is a major contributor to mor

100 ate markers have been explored, ranging from pulmonary function decline to biomarkers.

101 (n = 324) had ILD by HRCT and 46% displayed pulmonary function declines consistent with ILD progress

102 a role of CDC42 in the TH1 polarization and pulmonary function deficits found in patients with obesi

103 opic TH1-polarized systemic inflammation and pulmonary function deficits found in patients with pedia

104 enes, including RPS27L, were associated with pulmonary function deficits in obese children with asthm

105 response, with exacerbated IRIS and greater pulmonary function deficits than those in RAG2 and RAG/I

106 d systemic inflammation that correlates with pulmonary function deficits, but the pathways underlying

107 polarized inflammation that correlates with pulmonary function deficits.

108 Daily oscillations of pulmonary function depend on the rhythmic activity of th

109 function, assessed by annual brain imaging, pulmonary function, echocardiographic image, and laborat

110 cts of antacid therapy use from baseline for pulmonary function, exercise tolerance, survival, hospit

111 not seem to underlie GWAS associations with pulmonary function for common variants in ADAM19 and HTR

112 We also compared how pulmonary function, frequency of asthma exacerbations, a

113 Pulmonary function, gas exchange, and invasive hemodynam

114 nonimpaired measures of muscle strength and pulmonary function had significantly slower 4-m gait spe

115 tic current or former smokers with preserved pulmonary function have exacerbations, activity limitati

116 onship between genetic variation in HTR4 and pulmonary function identified in human GWAS.

117 8 of 30 patients with or without significant pulmonary function impairment.

118 Pulmonary function impairments are more common among peo

119 e, as well as its correlation with decreased pulmonary function in advanced IPF; (2) identifies IGF-1

120 LS patients, suggesting that PEA can enhance pulmonary function in ALS.

121 xtracellular matrix remodeling, and improved pulmonary function in bleomycin-treated mice.

122 variants, we studied the natural history of pulmonary function in correlation to motor abilities in

123 on between quantitative imaging features and pulmonary function in CT images.

124 ted whether differences exist in spirometric pulmonary function in healthy children across the Indian

125 tonin) receptor 4 (HTR4) are associated with pulmonary function in human GWASs.

126 ion was associated with diagnosed asthma and pulmonary function in Latino children and is an importan

127 on of acculturation measures with asthma and pulmonary function in Latino youth and determine whether

128 Prediction of postoperative pulmonary function in lung cancer patients before tumor

129 Prediction of post-operative pulmonary function in lung cancer patients before tumor

130 PS, and SPECT/CT in predicting postoperative pulmonary function in patients undergoing lobectomy.

131 PS and SPECT/CT in predicting post-operative pulmonary function in patients undergoing lobectomy.

132 RXFP1 expression is directly associated with pulmonary function in patients with IPF.

133 sruption of alveolar structure, a decline in pulmonary function, increase of rapamycin-sensitive expr

134 feature alterations occurred with worsening pulmonary function independent of an increase in disease

135 nificantly different from NRA with regard to pulmonary function indices, bronchial basement membrane

136 expression in the lung, locomotor activity, pulmonary function, inflammatory, pro-fibrotic and emphy

137 ates that nsv823469 plays a role in COPD and pulmonary function inheritance by potentially altering e

138 Integrative analyses reveal that pulmonary function instruments, including 73 novel varia

139 Obesity-related reduction in pulmonary function is a possible mechanism in the pathwa

140 Association of monocyte activation with pulmonary function is mediated by body mass index, where

141 ng principles by equipment manufacturers and pulmonary function laboratories can improve the interpre

142 ciety committee on Proficiency Standards for Pulmonary Function Laboratories has recognized the need

143 op chronic obstructive pulmonary disease and pulmonary function levels, including the forced expirato

144 kines, and loss of surfactant expression and pulmonary function linked to pathological features of ac

145 terminants (symptoms, rescue medication use, pulmonary function measure, and adherence estimates) wer

146 rrelation with noble gas MRI ventilation and pulmonary function measurements.

147 he relationships between the model, MRI, and pulmonary function measurements.

148 interleukin-6; miR-1180 was associated with pulmonary function measures at a marginally significant

149 The pulmonary function measures of forced expiratory volume

150 Less is known about acculturation and pulmonary function measures.

151 All measures considered for pulmonary function met consensus criteria for exclusion.

152 ithin CF airways, together with decreases in pulmonary function, mucus plugging and oxygen consumptio

153 ndrome (one [1%] vs one [1%]), and decreased pulmonary function (none vs one [1%]).

154 A decline in pulmonary function occurs 4 days after peak viral titer

155 improved the radiographic abnormalities and pulmonary function of patients with GLILD.

156 basis of a seven-category ordinal scale for pulmonary function on day 5.

157 No patient has developed worsening pulmonary function or acute or chronic rejection.

158 y meaningful improvements in asthma control, pulmonary function, or exacerbations in patients with se

159 admission, no differences in comorbidities, pulmonary function, or median sequential organ failure a

160 ted with carbon monoxide diffusion capacity, pulmonary function outcomes, and overall survival.

161 ography at Year 25 of CARDIA and measures of pulmonary function over 20 years in 3,000 participants.

162 oning and with greater subsequent decline in pulmonary functioning over time.

163 ed was used to examine the rate of change in pulmonary functioning over time.

164 001), as well as longitudinal differences in pulmonary function (P < .0001).

165 unction, cognition, mental health, survival, pulmonary function, pain, and muscle and/or nerve functi

166 Pulmonary function patterns were categorized based on th

167 ctive (HR 1.31; 95% CI: 0.64-2.32; P = .557) pulmonary function patterns were not associated with ear

168 lead to airway remodeling and a decrease in pulmonary function, producing morbidity.

169 sed survival, extreme weight loss, decreased pulmonary function, pulmonary haemorrhage and pathologic

170 tly with disease severity and inversely with pulmonary function, quality of life, and prognosis.

171 e primary outcome was measurement of newborn pulmonary function (ratio of the time to peak tidal expi

172 ry of body weight, a dramatic improvement in pulmonary function, reduced lung inflammation, and the r

173 tal capacity (FVC), a spirometric measure of pulmonary function, reflects lung volume and is used to

174 ging methods are not sensitive to changes in pulmonary function resulting from fibrosis.

175 phenotypes, we demonstrated that stroke and pulmonary function show enrichment for smoking-related g

176 tudy subjects, which included laboratory and pulmonary function studies, chest computed tomography, a

177 w-up visit during 2015, including a complete pulmonary function study and the EuroQol-5D and Beck Dep

178 The hallmarks of pulmonary function, such as histological lung injury sco

179 th and largely preserved cardiometabolic and pulmonary functions suggest the potential for near-full

180 tomography (CT) metrics on a lobar basis and pulmonary function test (PFT) results on a whole-lung ba

181 sing spondylitis (AS) and compared them with pulmonary function test (PFT) results, demographic chara

182 ctive pulmonary disease (COPD), based on the pulmonary function test (PFT), to correlate the various

183 patients with SSc should undergo a baseline pulmonary function test and lung HRCT screening to diagn

184 ell Disease, was constructed using the first pulmonary function test at >21 years of age.

185 Longitudinal changes in DW MRI and pulmonary function test measurements were assessed with

186 During an asthma exacerbation, pulmonary function test parameters (PFTs) return to thei

187 survey and had reliable post-bronchodilator pulmonary function test results and were thus included i

188 available in the United States; if baseline pulmonary function test results are normal to near norma

189 Pulmonary function test results before and after ARS rev

190 omputed tomography (HRCT) chest scans and/or pulmonary function test results in patients with CVID an

191 reatment and posttreatment HRCT scan scores, pulmonary function test results, and lymphocyte subsets

192 malignancy, and had available pretransplant pulmonary function test results.

193 evelop a new Technical Standard on reporting pulmonary function test results.

194 est, exercise), PaO2, hemoglobin, or resting pulmonary function test results.

195 A pulmonary function test was performed measuring prebronc

196 physician, 23.4% (13.9-36.6) had a previous pulmonary function test, and 5.6% (3.1-9.9) had been tre

197 .5 (range, 21.0-67.8) years at time of first pulmonary function test, and a median follow-up of 5.5 y

198 Background: Spirometry is the most common pulmonary function test.

199 Pulmonary function testing (PFT) is an important compone

200 Respiratory muscle function was assessed by pulmonary function testing (PFT).

201 ysis of variance, and the relationships with pulmonary function testing and eosinophil counts were as

202 dditional research about the roles of infant pulmonary function testing and food avoidance or dietary

203 univariable and multivariable analyses with pulmonary function testing and quality of life survey da

204 They also underwent pulmonary function testing at baseline CT and at 5 years

205 nt Gal-3 assessment using plasma samples and pulmonary function testing between 1995 and 1998.

206 thy lungs and are related to measurements of pulmonary function testing but not to eosinophil level.

207 ant linear correlations with measurements of pulmonary function testing but not with eosinophil level

208 d by the combination of imaging findings and pulmonary function testing decrements).

209 ing questionnaires or office-based screening pulmonary function testing or to determine the benefits

210 Pulmonary function testing reveals an obstructive ventil

211 volume was reproducible and correlated with pulmonary function testing severity, and it improved aft

212 Pulmonary function testing was performed according to gu

213 STL-1 Hypo) mice underwent lung morphometry, pulmonary function testing, and micro-computed tomograph

214 CT before and after surgery, with concurrent pulmonary function testing, body mass index calculation,

215 t included the completion of questionnaires, pulmonary function testing, chest computed tomography, a

216 Participants underwent pulmonary function testing, CT, and MRI.

217 ubjects underwent sputum and blood analyses, pulmonary function testing, exercise tolerance, and qual

218 as performed using questionnaires, atopy and pulmonary function testing, exhaled nitric oxide measure

219 ective standardized evaluation included full pulmonary function testing, high-resolution chest tomogr

220 and, according to their symptoms, underwent pulmonary function testing, methacholine challenge, spec

221 the patients were correlated with results of pulmonary function testing.

222 duration of illness, laboratory results and pulmonary function tests (PFT).

223 cystic fibrosis (CF), recurrent imaging and pulmonary function tests (PFTs) are needed for the asses

224 Pulmonary function tests (PFTs) are routinely used to as

225 erogeneity is greater in smokers with normal pulmonary function tests (PFTs) but who have visual evid

226 We sought to perform objective pulmonary function tests (PFTs) in HIV-infected and HEU

227 unenhanced supine CT scans of the chest and pulmonary function tests (PFTs) performed within 3 month

228 Pulmonary function tests (PFTs) that measured the diffus

229 earning algorithm and that obtained by using pulmonary function tests (PFTs) was then evaluated in th

230 ging session followed by clinically standard pulmonary function tests (PFTs), the 6-minute walk test,

231 s on chest radiographs (ten [67%] of 15) and pulmonary function tests (six [67%] of nine).

232 ho had undergone pre- and postbronchodilator pulmonary function tests and computed tomographic (CT) e

233 macular sub-layer thickness measurements and pulmonary function tests and disease duration.

234 postoperative pulmonary complications, while pulmonary function tests and the assessed indicators of

235 Pulmonary function tests and time since symptom onset we

236 Among survivors with normal pulmonary function tests at t1, females and survivors tr

237 ing or not having airflow limitation through pulmonary function tests before and after the use of a b

238 ompared with baseline CT fibrosis scores and pulmonary function tests by using Spearman rank correlat

239 In addition, pulmonary function tests revealed stable vital capacity

240 Pulmonary function tests showed low Dl(CO) (30% [12-79%]

241 Participants with CF also underwent pulmonary function tests the same day.

242 Pulmonary function tests were assessed at baseline (n =

243 The results of the pulmonary function tests were expressed as the percentag

244 tion and expiration, visual HRCT scores, and pulmonary function tests were obtained.

245 Bronchoalveolar lavage and pulmonary function tests were performed at intervals.

246 iagnosing BOS in patients with first drop of pulmonary function tests with a sensitivity of 96% and a

247 lassifications were associated with impaired pulmonary function tests, 6-minute walk distance, and St

248 All patients underwent pulmonary function tests, and measurement of fraction of

249 Pulmonary function tests, Asthma Control Test (ACT), Ast

250 bjects and 30 patients with asthma underwent pulmonary function tests, blood and sputum eosinophil co

251 We analyzed pulmonary function tests, blood, and bronchoscopic biops

252 e lymphatic edema, marked improvement in his pulmonary function tests, cessation of supplemental oxyg

253 onventional clinical measurements, including pulmonary function tests, during a period of disease sta

254 (F1), moderate (F2), or severe (F3) based on pulmonary function tests, high-resolution CT, and clinic

255 e range, 10-37 years) successfully underwent pulmonary function tests, hyperpolarized (3)He MRI, and

256 Pulmonary function tests, including diffusing capacity o

257 tion computed tomography (HRCT) patterns and pulmonary function tests, including the composite physio

258 7) and healthy controls (CON, n = 7) during pulmonary function tests, inspiratory endurance testing,

259 , with expertise in conducting and analyzing pulmonary function tests, laboratory quality assurance,

260 h SA and its specific characteristics (i.e., pulmonary function tests, quality of life scores, urgent

261 ment of lung, cardiac, and sleep function by pulmonary function tests, transthoracic echocardiography

262 radiomics data was compared to conventional pulmonary function tests.

263 need for a standardized reporting format for pulmonary function tests.

264 ndings are more sensitive as compared to the pulmonary function tests.

265 ar retinal nerve fiber layer correlates with pulmonary function tests.

266 ual scores and clinical parameters including pulmonary function tests.

267 standardized interview, skin prick tests and pulmonary function tests.

268 hickness, and body composition), asthma, and pulmonary function tests.

269 ee survival, modified Rodnan skin score, and pulmonary function tests.

270 ved in kidney angiomyolipoma size but not in pulmonary function tests.

271 gnant smokers significantly improved newborn pulmonary function tests.

272 Scale, grip strength, 5-meter walk test, and pulmonary function tests.

273 s these results in a new cohort using infant pulmonary function tests.

274 ase-extent contouring, which correlated with pulmonary function to assess CT images from patients wit

275 fibrosis with mild-to-moderate impairment in pulmonary function to receive a three-drug regimen of pr

276 cell counts, pro-inflammatory cytokines, and pulmonary function (total lung volume, static lung compl

277 , we unraveled biologic processes underlying pulmonary function traits and identified a candidate gen

278 ostoperative period for patients with normal pulmonary function undergoing general anesthesia with en

279 We assessed pulmonary function using a peak flow meter to measure FV

280 tric measures, cardiometabolic risk factors, pulmonary function, vitamin status, gastrointestinal sym

281 FeNO was quantified by NIOX Vero and pulmonary function was assessed by spirometry in 432 PLW

282 Pulmonary function was assessed every year in a Mexican

283 emphysema and fibrosis extents and change in pulmonary function was assessed using multivariate linea

284 We tested the hypothesis that abnormal pulmonary function was associated with earlier death.

285 IV) infection independent of risk behaviors, pulmonary function was evaluated in lifestyle-comparable

286 Vitamin D deficiency associated with pulmonary function was not statistically significant in

287 In univariate analysis impaired pulmonary function was significantly associated with gre

288 Worsening Week 4 lung inflammation and pulmonary function were both associated with greater inc

289 and sputum cell differentials or measures of pulmonary function were examined by using partial least

290 ailure liver subscore equals to 3 but stable pulmonary function were identified and received either s

291 of insulin resistance (HOMA-IR) and HDL, and pulmonary function were quantified in 168 adolescents, i

292 NHW in the COPDGene cohort, both measures of pulmonary function were significantly associated with SN

293 d microRNAs with inflammatory biomarkers and pulmonary function were tested with linear mixed effects

294 atients demonstrated a continuous decline in pulmonary function whereas the other had stable pulmonar

295 insults is essential for the preservation of pulmonary function, whereas failure or incomplete adapta

296 D025 resulted in normalization of pathogenic pulmonary function, which correlates with a marked reduc

297 han current or former smokers with preserved pulmonary function who were asymptomatic (CAT score, <10

298 inflammation with progression to compromised pulmonary function with age, reflecting the atopic march

299 also showed previously unexplored changes in pulmonary function, with AAV9-treated SOD1(G93A) mice di

300 iratory distress syndrome often recover full pulmonary function within six months.